This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The study was a non-randomised trial with concurrent controls carried out in a single centre. Patients received the VDD or DDD devices in alternating order. Concealment of allocation from the surgeon would not have been possible due to the nature of the intervention, concealment from the patient was not discussed. The mean duration of follow-up was 42 (SD 15) months ranging from 3 to 76 months. There seems to have been no losses to follow up. Assessment of outcomes does not appear to have been blinded.
Analysis of effectiveness
The basis for the analysis of effectiveness (intention to treat or treatment completers only) was not specified. It was not specified whether it was possible to maintain the alternating order for the implantation of devices. The primary outcome used in the analysis was a combined criterion of event free survival including survival of patients, absence of complications needing re-operation and maintenance of atrioventricular synchronised pacing mode. At analysis, groups were shown to be comparable in terms of age, sex, indication for pacing, left ventricular function, and concomitant diseases.
Effectiveness results
The study reported that there was no significant difference between VDD and DDD therapy with respect to event free survival of patients. The test statistic for the log-rank test used to compare the two therapies was 0.04.
Clinical conclusions
The percentage of event-free survival did not differ between patients with VDD pacemakers and DDD devices. Both pacemaker systems showed an equal therapeutic efficacy in patients with atrioventricular block and normal sinus node function.
Measure of benefits used in the economic analysis
As the effectiveness results showed no difference in the clinical benefit between the VDD and DDD devices, the economic analysis was based on cost differences only. The analysis was therefore a cost-minimisation study.
Direct costs
Some resources (mean hospital days) were reported separately from the costs. Mean prices and fees for individual cost items were reported. The perspective of the cost analysis was that of the hospital. Direct costs included the cost of devices, leads, single-use operation material and sterilisation, fees of implanting physicians, nurses and medical technicians. Furthermore, direct primary costs of pacemaker implantation included two nights of hospital stay, antibiotic prophylaxis with three doses of cefacolin, one routine pacemaker interrogation, one 24 hour Holter ECG and one chest X-ray. If hospitalisation was prolonged due to treatment of concomitant diseases not directly associated with pacemaker implantation, a hospital stay for an uncomplicated implantation was assumed. Direct secondary costs included costs of follow-up or complications of pacemaker therapy: hospital fees due to prolonged stay or re-admission of patients, cost of laboratory examinations and antibiotic therapy, cost of additional chest X-rays, Holter recordings and pacemaker interrogations, expenses due to operative revision, device explantation and re-implantation. Costs of treatment for atrial arrhythmia's were included as the condition could be associated with different pacemaking therapies. However, costs associated with coronary artery disease, myocardial infarction and heart failure were not included as it was considered that these were not directly associated with different dual-chamber pacing modes. Prices for devices and other materials were derived from the average price of various manufacturers calculated for a time period between 1992 and 1997. Personnel fees were taken from the standardised German hospital charges and charges for diagnostic devices were derived from the standardised German physician charges. The source of the cost of antibiotics and the day of hospital stay was not reported. The estimation of unit charges was based on standard published charges. Discounting was not conducted although the length of the study justified its use. The study reported average costs. No single price year was used. The costs were not adjusted for inflation.
